Global Anti-parasitic Drugs Market: Snapshot

The anti-parasitic drugs refers to that very particular type of medications that are meant for the purpose of treatment of various parasitic diseases, such as those caused by parasitic fungi, protozoa, helminths, ectoparasites, and amoeba  amongst many  others. Anti-parasitic drugs target and attack the parasitic agents of various infections and destroying them or restraining their growth and development. These drugs are generally effective and work well against a limited number of certain parasites within a very specific class of the parasites. Anti-parasitic drugs are one of those antimicrobial drugs that make an inclusion of antibiotics that target and destroy bacteria. They comprise those anti-fungals also which target and destroy fungi. These drugs could be administered topically, intravenously, and orally.

Some of the anti-parasitic drugs that are known for efficacy while treating a large range of  infections brought forth by different classes of parasites are broad-spectrum antibiotics for bacteria, broad-spectrum anti-parasitic, and analogous. 

 It is believed that almost all of the general and common human body infections that are caused by parasitic worm infections can be treated and cured with any one of the five anthelmintics that are used presently, namely diethylcarbamazine, ivermectin, albendazole, praziquantel and mebendazole. The aim of anthelmintic treatment is to reduce the infection intensity under the scale of clinical importance.

There are many factors that are attributed with the increasing prevalence of the said drugs. Factors such as affordability of the drugs, surging occurrences of parasitic infections, ease of direct purchase, and so on stimulate the growth of the said market.

Anti-parasitic drugs are medications that are used for the treatment of parasitic diseases caused by parasites such as fungi and protozoa. These drugs destroy or inhibit the growth of parasitic agents by targeting them. In a particular class, these medications are effective to a limited number of parasites. Parasitic infections can be severe, moderate, or mild. Ascariasis is one of the prevalent parasitic diseases. Other common infections are hookworm disease, trichomoniasis, and toxoplasmosis. The parasitic infections can result in nutritional deficiencies, fetal or neonatal harm, cutaneous nodules, and skin eruptions. Moreover, the infections may cause major damages to the central nervous system, lungs, eyes, heart, and liver. Anti-parasitic medications can be administered orally or intravenously, and these are one of the antimicrobial agents that include antibiotics that target bacteria. The World Health Organization (WHO) has suggested for public beneficial for the treatment of parasitic worm infections. Almost all of the common parasitic worm infections in the human body can be cured with one of five anthelmintics currently in use: mebendazole, albendazole, diethylcarbamazine, praziquantel, and ivermectin. The purpose of the anthelmintic treatment is to moderate the intensity of the infection beneath the level of clinical significance.

Factors such as rising prevalence of parasitic infections, increasing novel drug treatment, affordability of drugs, convenience of direct purchase, high adoption and acceptance in developing markets, and innovations and developments of drugs are driving the growth of the global anti-parasitic drugs market. However, certain factors such as stiff competition among existing players, high possibilities of substance abuse and addiction, complications and severity involved in taking wrong medications due to misdiagnosis or incorrect self-diagnosis, and lack of awareness among the rural population in developing and underdeveloped economies could restraint the global market growth during the forecast period.

The global anti-parasitic drugs market is classified on the basis of drug, disease indication, distribution channel, and geography. In terms of drug, the market is classified into anthelmintics, scabicides and pediculicides, antiprotozoals, and others. The anthelmintics sub-segment is further segmented into benzimidazole, ivermectin, and pyrantel. The scabicides and pediculicides sub-segment is further classified into lindane, benzyl benzoate, and others. The antiprotozoals sub-segment is classified into chloroquine, pyrimethamine, and others. In terms of disease indication, the anti-parasitic drugs market is segmented into giardiasis, trichuriasis, filariasis, neurocysticercosis, hydatid disease, pinworm disease, cysticercosis, ascariasis, and others. The key distribution channels of the anti-parasitic drugs market include hospital pharmacies, retail pharmacies, online pharmacies, mail order pharmacies, and others.

Geographically, the anti-parasitic drugs market has been segmented into five major regions: North America (U.S. and Canada), Europe (Germany, France, the U.K., etc.), Asia Pacific (Australia, China, Japan, India, etc.), Latin America (Brazil, Mexico, etc.), and Middle East & Africa (GCC Countries, South Africa, etc.). North America is the leading market for anti-parasitic drugs in terms of revenue, followed by Europe. The U.S. holds the largest share of the North America market. Asia Pacific and Latin America are emerging markets which are expected to witness significant growth rates during the forecast period. High growth rates in these regions are attributable to the increasing incidence of parasitic infections, rising health care industries, and growing government investment to develop health care infrastructure. The anti-parasitic drugs market in countries such as China, India, and Brazil is projected to expand at a high growth rate during the forecast period due to increase in awareness among the population about parasitic infections and their treatment.

Major players operating in the global market for anti-parasitic drugs include Arbor Pharmaceuticals Inc., Quepharma, Merck & Co., Inc., Cipla, Inc., Ipca Laboratories Ltd., Sun Pharmaceutical Industries Ltd., Guilin Pharmaceutical (Shanghai) Co., Ltd., Novartis AG, Mylan Labs, Ajanta Pharma, Sanofi, and AstraZeneca plc., Pfizer Inc., Bayer AG, GlaxoSmithKline, Alkem Laboratories Limited, Mankind Pharma, Indoco Remedies Ltd., Lincoln Pharmaceuticals Ltd., and Mallinckrodt Pharmaceuticals.

This study by TMR is all-encompassing framework of the dynamics of the market. It mainly comprises critical assessment of consumers' or customers' journeys, current and emerging avenues, and strategic framework to enable CXOs take effective decisions.

Our key underpinning is the 4-Quadrant Framework EIRS that offers detailed visualization of four elements:

  • Customer Experience Maps
  • Insights and Tools based on data-driven research
  • Actionable Results to meet all the business priorities
  • Strategic Frameworks to boost the growth journey

The study strives to evaluate the current and future growth prospects, untapped avenues, factors shaping their revenue potential, and demand and consumption patterns in the global market by breaking it into region-wise assessment.

The following regional segments are covered comprehensively:

  • North America
  • Asia Pacific
  • Europe
  • Latin America
  • The Middle East and Africa

The EIRS quadrant framework in the report sums up our wide spectrum of data-driven research and advisory for CXOs to help them make better decisions for their businesses and stay as leaders.

Below is a snapshot of these quadrants.

1. Customer Experience Map

The study offers an in-depth assessment of various customers’ journeys pertinent to the market and its segments. It offers various customer impressions about the products and service use. The analysis takes a closer look at their pain points and fears across various customer touchpoints. The consultation and business intelligence solutions will help interested stakeholders, including CXOs, define customer experience maps tailored to their needs. This will help them aim at boosting customer engagement with their brands.

2. Insights and Tools

The various insights in the study are based on elaborate cycles of primary and secondary research the analysts engage with during the course of research. The analysts and expert advisors at TMR adopt industry-wide, quantitative customer insights tools and market projection methodologies to arrive at results, which makes them reliable. The study not just offers estimations and projections, but also an uncluttered evaluation of these figures on the market dynamics. These insights merge data-driven research framework with qualitative consultations for business owners, CXOs, policy makers, and investors. The insights will also help their customers overcome their fears.

3. Actionable Results

The findings presented in this study by TMR are an indispensable guide for meeting all business priorities, including mission-critical ones. The results when implemented have shown tangible benefits to business stakeholders and industry entities to boost their performance. The results are tailored to fit the individual strategic framework. The study also illustrates some of the recent case studies on solving various problems by companies they faced in their consolidation journey.

4. Strategic Frameworks

The study equips businesses and anyone interested in the market to frame broad strategic frameworks. This has become more important than ever, given the current uncertainty due to COVID-19. The study deliberates on consultations to overcome various such past disruptions and foresees new ones to boost the preparedness. The frameworks help businesses plan their strategic alignments for recovery from such disruptive trends. Further, analysts at TMR helps you break down the complex scenario and bring resiliency in uncertain times.

The report sheds light on various aspects and answers pertinent questions on the market. Some of the important ones are:

1. What can be the best investment choices for venturing into new product and service lines?

2. What value propositions should businesses aim at while making new research and development funding?

3. Which regulations will be most helpful for stakeholders to boost their supply chain network?

4. Which regions might see the demand maturing in certain segments in near future?

5. What are the some of the best cost optimization strategies with vendors that some well-entrenched players have gained success with?

6. Which are the key perspectives that the C-suite are leveraging to move businesses to new growth trajectory?

7. Which government regulations might challenge the status of key regional markets?

8. How will the emerging political and economic scenario affect opportunities in key growth areas?

9. What are some of the value-grab opportunities in various segments?

10. What will be the barrier to entry for new players in the market?

Note: Although care has been taken to maintain the highest levels of accuracy in TMR’s reports, recent market/vendor-specific changes may take time to reflect in the analysis.

Enquiry Before Buying

TMR offers Enquiry Before Buying that help clients to get information on their business scenario required where syndicated solutions are not enough.

Enquiry Before Buying

Antiparasitic Drugs Market